Literature DB >> 28768310

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.

Marc S Sabatine1,2, Robert P Giugliano1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28768310     DOI: 10.1001/jamacardio.2017.2293

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  4 in total

1.  Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

Authors:  Marc S Sabatine; Stephen D Wiviott; KyungAh Im; Sabina A Murphy; Robert P Giugliano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

2.  Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

Authors:  Robert P Giugliano; Anthony Keech; Sabina A Murphy; Kurt Huber; S Lale Tokgozoglu; Basil S Lewis; Jorge Ferreira; Armando Lira Pineda; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

3.  Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded "Double-Trouble" Lipid Profile in Overweight/Obese.

Authors:  Francesco Spannella; Federico Giulietti; Chiara Di Pentima; Riccardo Sarzani
Journal:  Adv Ther       Date:  2019-04-05       Impact factor: 3.845

Review 4.  Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence.

Authors:  Giulia Maria Camerino; Nancy Tarantino; Ileana Canfora; Michela De Bellis; Olimpia Musumeci; Sabata Pierno
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.